

MEDICAL POLICY

POLICY TITLE	GENETIC AND PROTEIN BIOMARKERS FOR THE DIAGNOSIS AND CANCER RISK ASSESSMENT OF PROSTATE CANCER
POLICY NUMBER	MP 2.280

CLINICAL BENEFIT	<input type="checkbox"/> MINIMIZE SAFETY RISK OR CONCERN. <input checked="" type="checkbox"/> MINIMIZE HARMFUL OR INEFFECTIVE INTERVENTIONS. <input type="checkbox"/> ASSURE APPROPRIATE LEVEL OF CARE. <input type="checkbox"/> ASSURE APPROPRIATE DURATION OF SERVICE FOR INTERVENTIONS. <input type="checkbox"/> ASSURE THAT RECOMMENDED MEDICAL PREREQUISITES HAVE BEEN MET. <input type="checkbox"/> ASSURE APPROPRIATE SITE OF TREATMENT OR SERVICE.
Effective Date:	RETIRED 7/1/2026

POLICY

Genetic and protein biomarkers for the diagnosis of prostate cancer, including, but not limited to the following, are considered **investigational**:

- Kallikrein markers (e.g., 4KscoreTest)
- Prostate Health Index (PHI)
- *HOXC6* and *DLX1* testing (e.g., SelectMDx)
- PCA3, ERG, and SPDEF RNA expression in exosomes (e.g., ExoDx Prostate IntelliScore)
- Autoantibodies ARF 6, NKX3-1, 5-UTR-BMI1, CEP 164, 3-UTR-Ropporin, Desmocollin, AURKAIP-1, and CSNK2A2 (e.g., Apifyny)
- PCA3 testing (e.g., ProgenSA PCA3 Assay)
- *TMPRSS: ERG* fusion genes (e.g., MyProstate Score)
- Gene hypermethylation testing (e.g., ConfirmMDx)
- Mitochondrial DNA mutation testing (e.g., Prostate Core Mitomics Test)
- PanGIA Prostate
- Candidate gene panels

Single nucleotide variant testing for cancer risk assessment of prostate cancer is considered **investigational**. There is insufficient evidence to support a conclusion concerning the health outcomes or benefits associated with the above procedures.

Cross-References

MP 2.259 Molecular Panel Testing of Cancers to Identify Targeted Therapies

MP 2.263 Gene Expression Profiling, Protein Biomarkers, and Multimodal Artificial Intelligence for Prostate Cancer Management

MP 2.267 Circulating Tumor DNA and Circulating Tumor Cells for Cancer Management (Liquid Biopsy)

MP 2.277 Investigational Miscellaneous Genetic and Molecular Tests

MEDICAL POLICY

POLICY TITLE	GENETIC AND PROTEIN BIOMARKERS FOR THE DIAGNOSIS AND CANCER RISK ASSESSMENT OF PROSTATE CANCER
POLICY NUMBER	MP 2.280

PRODUCT VARIATIONS

This policy is only applicable to certain programs and products administered by Capital Blue Cross and subject to benefit variations. Please see additional information below.

FEP PPO: Refer to FEP Medical Policy Manual. The FEP Medical Policy manual can be found at: <https://www.fepblue.org/benefit-plans/medical-policies-and-utilization-management-guidelines/medical-policies>

DESCRIPTION/BACKGROUND

PROSTATE CANCER

Prostate cancer is the most common cancer, and the second most common cause of cancer death in men. Prostate cancer is a complex, heterogeneous disease, ranging from microscopic tumors unlikely to be life-threatening to aggressive tumors that can metastasize, leading to morbidity or death. Early localized disease can usually be treated with surgery and radiotherapy, although active surveillance may be adopted in men whose cancer is unlikely to cause major health problems during their lifespan or for whom the treatment might be dangerous. In patients with inoperable or metastatic disease, treatment consists of hormonal therapy and possibly chemotherapy. The lifetime risk of being diagnosed with prostate cancer for men in the U.S. is approximately 16%, while the risk of dying of prostate cancer is 3%. African American men have the highest prostate cancer risk in the U.S.; the incidence of prostate cancer is about 60% higher and the mortality rate is more than 2 to 3 times greater than that of White men. Autopsy results have suggested that about 30% of men over the age of 55 and 60% of men over the age of 80 who die of other causes have incidental prostate cancer, indicating that many cases of cancer are unlikely to pose a threat during a man's life expectancy.

Grading

The most widely used grading scheme for prostate cancer is the Gleason system. It is an architectural grading system ranging from 1 (well-differentiated) to 5 (undifferentiated); the score is the sum of the primary and secondary patterns. A Gleason score of 6 or less is low-grade prostate cancer that usually grows slowly; 7 is an intermediate grade; 8 to 10 is high-grade cancer that grows more quickly. A revised prostate cancer grading system has been adopted by the National Cancer Institute and the World Health Organization. A cross-walk of these grading systems is shown in Table 1.

Table 1. Prostate Cancer Grading Systems

Grade Group	Gleason Score (Primary and Secondary Pattern)	Cells
1	6 or less	Well-differentiated (low grade)
2	7 (3+4)	Moderately differentiated (moderate grade)

MEDICAL POLICY

POLICY TITLE	GENETIC AND PROTEIN BIOMARKERS FOR THE DIAGNOSIS AND CANCER RISK ASSESSMENT OF PROSTATE CANCER
POLICY NUMBER	MP 2.280

3	7 (4+3)	Poorly differentiated (high grade)
4	8	Undifferentiated (high grade)
5	9 to 10	Undifferentiated (high grade)

Numerous genetic alterations associated with the development or progression of prostate cancer have been described, with the potential for the use of these molecular markers to improve the selection process of men who should undergo prostate biopsy or rebiopsy after an initial negative biopsy.

Regulatory Status

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments (CLIA). Laboratories that offer laboratory-developed tests must be licensed under the CLIA for high-complexity testing. The following laboratories are certified under the CLIA: BioReference Laboratories and GenPath Diagnostics (subsidiaries of OPKO Health; 4Kscore®), ARUP Laboratories, Mayo Medical Laboratories, LabCorp, BioVantra, others (PCA3 assay), Clinical Research Laboratory (Prostate Core Mitomic Test™), MDx Health (SelectMDx, ConfirMDx), Innovative Diagnostics (PHI™), and ExoDx® Prostate (Exosome Diagnostics). To date, the U.S. Food and Drug Administration (FDA) has chosen not to require any regulatory review of these tests.

In February 2012, the Progenesa® PCA3 Assay (Gen-Probe; now Hologic) was approved by the FDA through the premarket approval process. The Progenesa PCA3 Assay has been approved by the FDA to aid in the decision for repeat biopsy in men 50 years or older who have had 1 or more negative prostate biopsies and for whom a repeat biopsy would be recommended based on the current standard of care. The Progenesa PCA3 Assay should not be used for men with atypical small acinar proliferation on their most recent biopsy. FDA product code: OYM.

In June 2012, proPSA, a blood test used to calculate the Prostate Health Index (PHI ; Beckman Coulter) was approved by the FDA through the premarket approval process. The PHI test is indicated as an aid to distinguish prostate cancer from a benign prostatic condition in men ages 50 and older with prostate-specific antigen levels of 4 to 10 ng/mL and with digital rectal exam findings that are not suspicious. According to the manufacturer, the test reduces the number of prostate biopsies. FDA product code: OYA.

RATIONALE

Summary of Evidence

For individuals who are being considered for an initial prostate biopsy who receive testing for genetic and protein biomarkers of prostate cancer (e.g., kallikreins biomarkers and 4Kscore Test, proPSA and Prostate Health Index, TMPRSS fusion genes and MyProstateScore, SelectMDx for Prostate Cancer, ExoDx Prostate, Apifyny, PCA3 score, and PanGIA Prostate),

MEDICAL POLICY

POLICY TITLE	GENETIC AND PROTEIN BIOMARKERS FOR THE DIAGNOSIS AND CANCER RISK ASSESSMENT OF PROSTATE CANCER
POLICY NUMBER	MP 2.280

the evidence includes systematic reviews, meta-analyses, and primarily observational studies. Relevant outcomes are overall survival, disease-specific survival, test validity, resource utilization, and quality of life. The evidence supporting clinical utility varies by the test but has not been directly shown for any biomarker test. Absent direct evidence of clinical utility, a chain of evidence might be constructed. However, the performance of biomarker testing for directing biopsy referrals is uncertain. While some studies have shown a reduction or delay in biopsy based on testing, a chain of evidence for clinical utility cannot be constructed due to limitations in clinical validity. Test validation populations have included men with a positive digital rectal exam (DRE), a prostate-specific antigen (PSA) level outside of the gray zone (between 3 or 4 ng/mL and 10 ng/mL), or older men for whom the information from test results are less likely to be informative. Many biomarker tests do not have standardized cutoffs to recommend a biopsy. In addition, comparative studies of the many biomarkers are lacking. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who are being considered for repeat biopsy who receive testing for genetic and protein biomarkers of prostate cancer (e.g., PCA3 score, Gene Hypermethylation and ConfirmMDx test, Prostate Core Mitomics Test, MyProstate Score), the evidence includes systematic reviews and meta-analyses and primarily observational studies. Relevant outcomes are overall survival, disease-specific survival, test validity, resource utilization, and quality of life. The performance of biomarker testing for guiding rebiopsy decisions is lacking. The tests are associated with a diagnosis of prostate cancer and aggressive prostate cancer, but studies on clinical validity are limited and do not compare performance characteristics with standard risk prediction models. Direct evidence supporting clinical utility has not been shown. No data are currently available on the longer-term clinical outcomes of the use of genetic and protein biomarkers to decide on repeat prostate biopsy. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

DEFINITIONS

NA

DISCLAIMER

Capital Blue Cross' medical policies are used to determine coverage for specific medical technologies, procedures, equipment, and services. These medical policies do not constitute medical advice and are subject to change as permitted by law or applicable clinical evidence from independent treatment guidelines. Treating providers are solely responsible for medical advice and treatment of members. These policies are not a guarantee of coverage or payment. Payment of claims is subject to a determination regarding the member's benefit program and eligibility on the date of service, and a determination that the services are medically necessary and appropriate. Final processing of a claim is based upon the terms of contract that applies to the members' benefit program, including benefit limitations and exclusions. If a provider or a member has a question concerning this medical policy, please contact Capital Blue Cross' Provider Services or Member Services.

MEDICAL POLICY

POLICY TITLE	GENETIC AND PROTEIN BIOMARKERS FOR THE DIAGNOSIS AND CANCER RISK ASSESSMENT OF PROSTATE CANCER
POLICY NUMBER	MP 2.280

CODING INFORMATION

Note: This list of codes may not be all-inclusive, and codes are subject to change at any time. The identification of a code in this section does not denote coverage as coverage is determined by the terms of member benefit information. In addition, not all covered services are eligible for separate reimbursement.

Investigational for the diagnosis and cancer risk assessment of prostate cancer, therefore, not covered:

CPT Codes®								
81313	81479	81539	81551	0011M	0005U	0021U	0113U	0228U
0339U	0343U	0359U	0403U	0424U	0433U	0495U	0497U	0534U
0550U	0609U							

REFERENCES

1. Howlader N, Noone AM, Krapcho M, et al. *SEER Cancer Statistics Review, 1975-2014*. Bethesda, MD: National Cancer Institute; 2017.
2. Odedina FT, Akinremi TO, Chinegwundoh F, et al. Prostate cancer disparities in Black men of African descent: a comparative literature review of prostate cancer burden among Black men in the United States, Caribbean, United Kingdom, and West Africa. *Infect Agent Cancer*. Feb 10 2009; 4 Suppl 1(Suppl 1): S2. PMID 19208207
3. Bell KJ, Del Mar C, Wright G, et al. Prevalence of incidental prostate cancer: A systematic review of autopsy studies. *Int J Cancer*. Oct 01 2015; 137(7): 1749-57. PMID 25821151
4. Gleason DF. Classification of prostatic carcinomas. *Cancer Chemother Rep*. Mar 1966; 50(3): 125-8. PMID 5948714
5. National Cancer Institute. *SEER Database*. <https://seer.cancer.gov/seerinqury/index.php?page=view&id=20170036&type=q>. Accessed September 16, 2024.
6. Hoogendam A, Buntinx F, de Vet HC. The diagnostic value of digital rectal examination in primary care screening for prostate cancer: a meta-analysis. *Fam Pract*. Dec 1999; 16(6): 621-6. PMID 10625141
7. Gosselaar C, Roobol MJ, Roemeling S, et al. The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam. *Eur Urol*. Sep 2008; 54(3): 581-8. PMID 18423977
8. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level or =4.0 ng per milliliter. *N Engl J Med*. May 27 2004; 350(22): 2239-46. PMID 15163773
9. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. *N Engl J Med*. Apr 25 1991; 324(17): 1156-61. PMID 1707140
10. Aus G, Bergdahl S, Lodding P, et al. Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer--results from a prospective,

MEDICAL POLICY

POLICY TITLE	GENETIC AND PROTEIN BIOMARKERS FOR THE DIAGNOSIS AND CANCER RISK ASSESSMENT OF PROSTATE CANCER
POLICY NUMBER	MP 2.280

- population-based randomized controlled trial. *Eur Urol.* Mar 2007; 51(3): 659-64. PMID 16934392
11. Buzzoni C, Auvinen A, Roobol MJ, et al. Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate Cancer. *Eur Urol.* Nov 2015; 68(5): 885-90. PMID 25791513
 12. Arnsrud Godtman R, Holmberg E, Lilja H, et al. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial. *Eur Urol.* Sep 2015; 68(3): 354-60. PMID 25556937
 13. Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. *Lancet Oncol.* Aug 2010; 11(8): 725-32. PMID 20598634
 14. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. *N Engl J Med.* Mar 26 2009; 360(13): 1320-8. PMID 19297566
 15. Wolf AM, Wender RC, Etzioni RB, et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. *CA Cancer J Clin.* 2010; 60(2): 70-98. PMID 20200110
 16. Rosario DJ, Lane JA, Metcalfe C, et al. Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study. *BMJ.* Jan 09 2012; 344: d7894. PMID 22232535
 17. Liss M, Ehdaie B, Loeb S, et al. The Prevention and Treatment of the More Common Complications Related to Prostate Biopsy Update. 2012; updated 2016; <https://www.auanet.org/guidelines-and-quality/guidelines/best-practice-statements-and-whitepapers/prostate-needle-biopsy-complications>. Accessed September 16, 2024.
 18. Lavallée LT, Binette A, Witiuk K, et al. Reducing the Harm of Prostate Cancer Screening: Repeated Prostate-Specific Antigen Testing. *Mayo Clin Proc.* Jan 2016; 91(1): 17-22. PMID 26688045
 19. Ruiz-Aragón J, Márquez-Peláez S. [Assessment of the PCA3 test for prostate cancer diagnosis: a systematic review and meta-analysis]. *Actas Urol Esp.* Apr 2010; 34(4): 346-55. PMID 20470697
 20. Mackinnon AC, Yan BC, Joseph LJ, et al. Molecular biology underlying the clinical heterogeneity of prostate cancer: an update. *Arch Pathol Lab Med.* Jul 2009; 133(7): 1033-40. PMID 19642730
 21. Partin AW, Brawer MK, Subong EN, et al. Prospective evaluation of percent free-PSA and complexed-PSA for early detection of prostate cancer. *Prostate Cancer Prostatic Dis.* Jun 1998; 1(4): 197-203. PMID 12496895
 22. Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. *J Natl Cancer Inst.* Apr 19 2006; 98(8): 529-34. PMID 16622122
 23. van Vugt HA, Roobol MJ, Kranse R, et al. Prediction of prostate cancer in unscreened men: external validation of a risk calculator. *Eur J Cancer.* Apr 2011; 47(6): 903-9. PMID 21163642

MEDICAL POLICY

POLICY TITLE	GENETIC AND PROTEIN BIOMARKERS FOR THE DIAGNOSIS AND CANCER RISK ASSESSMENT OF PROSTATE CANCER
POLICY NUMBER	MP 2.280

24. Rosenkrantz AB, Verma S, Choyke P, et al. Prostate Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Patients with a Prior Negative Biopsy: A Consensus Statement by AUA and SAR. *J Urol*. Dec 2016; 196(6): 1613-1618. PMID 27320841
25. Mi C, Bai L, Yang Y, et al. 4Kscore diagnostic value in patients with high-grade prostate cancer using cutoff values of 7.5% to 10%: A meta-analysis. *Urol Oncol*. Jun 2021; 39(6): 366.e1-366.e10. PMID 33685800
26. Kawada T, Shim SR, Quhal F, et al. Diagnostic Accuracy of Liquid Biomarkers for Clinically Significant Prostate Cancer Detection: A Systematic Review and Diagnostic Meta-analysis of Multiple Thresholds. *Eur Urol Oncol*. Aug 2024; 7(4): 649-662. PMID 37981495
27. Russo GI, Regis F, Castelli T, et al. A Systematic Review and Meta-analysis of the Diagnostic Accuracy of Prostate Health Index and 4-Kallikrein Panel Score in Predicting Overall and High-grade Prostate Cancer. *Clin Genitourin Cancer*. Aug 2017; 15(4): 429-439.e1. PMID 28111174
28. Bhattu AS, Zappala SM, Parekh DJ, et al. A 4Kscore Cut-off of 7.5% for Prostate Biopsy Decisions Provides High Sensitivity and Negative Predictive Value for Significant Prostate Cancer. *Urology*. Feb 2021; 148: 53-58. PMID 33217456
29. Stattin P, Vickers AJ, Sjoberg DD, et al. Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study. *Eur Urol*. Aug 2015; 68(2): 207-13. PMID 25682340
30. Loeb S, Shin SS, Broyles DL, et al. Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer. *BJU Int*. Jul 2017; 120(1): 61-68. PMID 27743489
31. Parekh DJ, Punnen S, Sjoberg DD, et al. A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer. *Eur Urol*. Sep 2015; 68(3): 464-70. PMID 25454615
32. Konety B, Zappala SM, Parekh DJ, et al. The 4Kscore® Test Reduces Prostate Biopsy Rates in Community and Academic Urology Practices. *Rev Urol*. 2015; 17(4): 231-40. PMID 26839521
33. Pecoraro V, Roli L, Plebani M, et al. Clinical utility of the (-2)proPSA and evaluation of the evidence: a systematic review. *Clin Chem Lab Med*. Jul 01 2016; 54(7): 1123-32. PMID 26609863
34. Anyango R, Ojwando J, Mwita C, et al. Diagnostic accuracy of [-2]proPSA versus Gleason score and Prostate Health Index versus Gleason score for the determination of aggressive prostate cancer: a systematic review. *JBIM Evid Synth*. Jun 2021; 19(6): 1263-1291. PMID 33741840
35. Catalona WJ, Partin AW, Sanda MG, et al. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. *J Urol*. May 2011; 185(5): 1650-5. PMID 21419439
36. Tosoian JJ, Druskin SC, Andreas D, et al. Use of the Prostate Health Index for detection of prostate cancer: results from a large academic practice. *Prostate Cancer Prostatic Dis*. Jun 2017; 20(2): 228-233. PMID 28117387

MEDICAL POLICY

POLICY TITLE	GENETIC AND PROTEIN BIOMARKERS FOR THE DIAGNOSIS AND CANCER RISK ASSESSMENT OF PROSTATE CANCER
POLICY NUMBER	MP 2.280

37. White J, Shenoy BV, Tutrone RF, et al. Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting. *Prostate Cancer Prostatic Dis.* Apr 2018; 21(1): 78-84. PMID 29158509
38. Sanda MG, Feng Z, Howard DH, et al. Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer. *JAMA Oncol.* Aug 01 2017; 3(8): 1085-1093. PMID 28520829
39. Tomlins SA, Day JR, Lonigro RJ, et al. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. *Eur Urol.* Jul 2016; 70(1): 45-53. PMID 25985884
40. Ankerst DP, Goros M, Tomlins SA, et al. Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator. *Eur Urol Focus.* Jan 2019; 5(1): 54-61. PMID 29422418
41. Tosoian JJ, Trock BJ, Morgan TM, et al. Use of the MyProstateScore Test to Rule Out Clinically Significant Cancer: Validation of a Straightforward Clinical Testing Approach. *J Urol.* Mar 2021; 205(3): 732-739. PMID 33080150
42. Newcomb LF, Zheng Y, Faino AV, et al. Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS). *Prostate Cancer Prostatic Dis.* Sep 2019; 22(3): 438-445. PMID 30664734
43. Van Neste L, Hendriks RJ, Dijkstra S, et al. Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score. *Eur Urol.* Nov 2016; 70(5): 740-748. PMID 27108162
44. McKiernan J, Donovan MJ, O'Neill V, et al. A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy. *JAMA Oncol.* Jul 01 2016; 2(7): 882-9. PMID 27032035
45. Tutrone R, Donovan MJ, Torkler P, et al. Clinical utility of the exosome based ExoDx Prostate(IntelliScore) EPI test in men presenting for initial Biopsy with a PSA 2-10 ng/mL. *Prostate Cancer Prostatic Dis.* Dec 2020; 23(4): 607-614. PMID 32382078
46. Tutrone R, Lowentritt B, Neuman B, et al. ExoDx prostate test as a predictor of outcomes of high-grade prostate cancer - an interim analysis. *Prostate Cancer Prostatic Dis.* Sep 2023; 26(3): 596-601. PMID 37193776
47. Schipper M, Wang G, Giles N, et al. Novel prostate cancer biomarkers derived from autoantibody signatures. *Transl Oncol.* Apr 2015; 8(2): 106-11. PMID 25926076
48. Wysock JS, Becher E, Persily J, et al. Concordance and Performance of 4Kscore and SelectMDx for Informing Decision to Perform Prostate Biopsy and Detection of Prostate Cancer. *Urology.* Jul 2020; 141: 119-124. PMID 32294481
49. Cui Y, Cao W, Li Q, et al. Evaluation of prostate cancer antigen 3 for detecting prostate cancer: a systematic review and meta-analysis. *Sci Rep.* May 10 2016; 6: 25776. PMID 27161545
50. Rodríguez SVM, García-Perdomo HA. Diagnostic accuracy of prostate cancer antigen 3 (PCA3) prior to first prostate biopsy: A systematic review and meta-analysis. *Can Urol Assoc J.* May 2020; 14(5): E214-E219. PMID 31793864
51. Nicholson A, Mahon J, Boland A, et al. The clinical effectiveness and cost-effectiveness of the PROGENSA® prostate cancer antigen 3 assay and the Prostate Health Index in

MEDICAL POLICY

POLICY TITLE	GENETIC AND PROTEIN BIOMARKERS FOR THE DIAGNOSIS AND CANCER RISK ASSESSMENT OF PROSTATE CANCER
POLICY NUMBER	MP 2.280

- the diagnosis of prostate cancer: a systematic review and economic evaluation. Health Technol Assess. Oct 2015; 19(87): i-xxxi, 1-191. PMID 26507078*
52. *Wei JT, Feng Z, Partin AW, et al. Can urinary PCA3 supplement PSA in the early detection of prostate cancer?. J Clin Oncol. Dec 20 2014; 32(36): 4066-72. PMID 25385735*
 53. *Hennenlotter J, Neumann T, Alperowitz S, et al. Age-Adapted Prostate Cancer Gene 3 Score Interpretation - Suggestions for Clinical Use. Clin Lab. Mar 01 2020; 66(3). PMID 32162868*
 54. *Vickers AJ, Gupta A, Savage CJ, et al. A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening. Cancer Epidemiol Biomarkers Prev. Feb 2011; 20(2): 255-61. PMID 21148123*
 55. *Ruffion A, Devonec M, Champetier D, et al. PCA3 and PCA3-based nomograms improve diagnostic accuracy in patients undergoing first prostate biopsy. Int J Mol Sci. Aug 29 2013; 14(9): 17767-80. PMID 23994838*
 56. *Ruffion A, Perrin P, Devonec M, et al. Additional value of PCA3 density to predict initial prostate biopsy outcome. World J Urol. Aug 2014; 32(4): 917-23. PMID 24500192*
 57. *Merdan S, Tomlins SA, Barnett CL, et al. Assessment of long-term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy. Cancer. Nov 15 2015; 121(22): 4071-9. PMID 26280815*
 58. *Djavan B, Waldert M, Zlotta A, et al. Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study. J Urol. Sep 2001; 166(3): 856-60. PMID 11490233*
 59. *Lujan M, Paez A, Santonja C, et al. Prostate cancer detection and tumor characteristics in men with multiple biopsy sessions. Prostate Cancer Prostatic Dis. 2004; 7(3): 238-42. PMID 15289810*
 60. *Stewart GD, Van Neste L, Delvenne P, et al. Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC study. J Urol. Mar 2013; 189(3): 1110-6. PMID 22999998*
 61. *Partin AW, Van Neste L, Klein EA, et al. Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies. J Urol. Oct 2014; 192(4): 1081-7. PMID 24747657*
 62. *Waterhouse RL, Van Neste L, Moses KA, et al. Evaluation of an Epigenetic Assay for Predicting Repeat Prostate Biopsy Outcome in African American Men. Urology. Jun 2019; 128: 62-65. PMID 29660369*
 63. *Van Neste L, Partin AW, Stewart GD, et al. Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies. Prostate. Sep 2016; 76(12): 1078-87. PMID 27121847*
 64. *Partin AW, VAN CRIEKINGE W, TROCK BJ, et al. CLINICAL EVALUATION OF AN EPIGENETIC ASSAY TO PREDICT MISSED CANCER IN PROSTATE BIOPSY SPECIMENS. Trans Am Clin Climatol Assoc. 2016; 127: 313-327. PMID 28066067*
 65. *Food and Drug Administration. Summary of Safety and Effectiveness Data. PMA P090026. Quantitative test for determination of [-2]proPSA levels. Silver Spring, MD: Food and Drug Administration; 2012.*

MEDICAL POLICY

POLICY TITLE	GENETIC AND PROTEIN BIOMARKERS FOR THE DIAGNOSIS AND CANCER RISK ASSESSMENT OF PROSTATE CANCER
POLICY NUMBER	MP 2.280

66. Aubry W, Lieberthal R, Willis A, et al. Budget impact model: epigenetic assay can help avoid unnecessary repeated prostate biopsies and reduce healthcare spending. *Am Health Drug Benefits*. Jan 2013; 6(1): 15-24. PMID 24991343
67. Robinson K, Creed J, Reguly B, et al. Accurate prediction of repeat prostate biopsy outcomes by a mitochondrial DNA deletion assay. *Prostate Cancer Prostatic Dis*. Jun 2010; 13(2): 126-31. PMID 20084081
68. Legisi L, DeSa E, Qureshi MN. Use of the Prostate Core Mitomic Test in Repeated Biopsy Decision-Making: Real-World Assessment of Clinical Utility in a Multicenter Patient Population. *Am Health Drug Benefits*. Dec 2016; 9(9): 497-502. PMID 28465777
69. Leyten GH, Hessels D, Smit FP, et al. Identification of a Candidate Gene Panel for the Early Diagnosis of Prostate Cancer. *Clin Cancer Res*. Jul 01 2015; 21(13): 3061-70. PMID 25788493
70. Xiao K, Guo J, Zhang X, et al. Use of two gene panels for prostate cancer diagnosis and patient risk stratification. *Tumour Biol*. Aug 2016; 37(8): 10115-22. PMID 26820133
71. Tosoian JJ, Sessine MS, Trock BJ, et al. MyProstateScore in men considering repeat biopsy: validation of a simple testing approach. *Prostate Cancer Prostatic Dis*. Sep 2023; 26(3): 563-567. PMID 36585434
72. Wei JT, Barocas D, Carlsson S, et al. Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening. *J Urol*. Jul 2023; 210(1): 46-53. PMID 37096582
73. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: prostate cancer early detection V.2.2024. https://www.nccn.org/professionals/physician_gls/pdf/prostate_detection.pdf. Accessed September 16, 2024.
74. National Institute for Health and Care Excellence (NICE). Prostate cancer: diagnosis and management [NG131]. 2019. Updated December 15, 2021; <https://www.nice.org.uk/guidance/ng131/chapter/Recommendations#assessment-and-diagnosis>. Accessed September 16, 2024.
75. U. S. Preventive Services Task Force. Prostate Cancer: Screening. 2018; <https://www.uspreventiveservicestaskforce.org/uspstf/draft-update-summary/prostate-cancer-screening-adults>. Accessed September 16, 2024.

POLICY HISTORY

MP 2.280	01/01/2020 Administrative Update. Added new codes effective 01/01/2020: 81552, 81559, 0011M, 0005U, 0021U, 0053U, and 0113U.
	08/19/2020 Consensus Review. No change in policy statement. Removed codes 81552 and 81559. Added Genetic counseling segment under policy guidelines. References and background updated.
	11/30/2020 Major Review. Added medically necessary criteria for Gene expression profile analysis for the evaluation of prostate cancer based on NCCN Biomarker Compendium. Revised, statement, guidelines, references, and coding.

MEDICAL POLICY

POLICY TITLE	GENETIC AND PROTEIN BIOMARKERS FOR THE DIAGNOSIS AND CANCER RISK ASSESSMENT OF PROSTATE CANCER
POLICY NUMBER	MP 2.280

	12/29/2021 Minor Review. Changed title of policy. Updated MN criteria for management of prostate cancer as well as policy guidelines. Updated FEP, Background, and references. Added code 81542 to MN coding table.
	08/29/2022 Minor Review. Removed Promark as MN. Other management testing is now NMN. miR Sentinel™ test added to INV diagnosis tests. Updated guidelines, FEP, background, rationale, and references. Added 0228U, 0339U, and 0343U to INV coding table.
	12/01/2022 Administrative Update. Added new code 0359U effective 01/01/2023
	06/13/2023 Administrative Update. Deleted 0053U effective 07/01/2023
	09/07/2023 Administrative Update. Added new code 0403U. Effective date 10/01/2023.
	12/08/2023 Consensus Review. Updated cross-references and references. No changes to coding.
	12/12/2023 Administrative Update. Added codes 0424U and 0433U.
	09/18/2024 Administrative Update. New codes 0495U, 0497U, 0513U added effective 10/01/2024.
	10/21/2024 Minor Review. Modified criteria for management tests. Added INV statement for multimodal artificial intelligence assays. Updated coding table; added 0376U. Updated background, rationale, and references.
	03/12/2025 Administrative Update. New codes 0534U and 0550U added. Effective date 04/01/2025
	10/10/2025 Minor Review. Removed management test statements and procedure codes to MP 2.263. Diagnosis and Cancer Risk Assessment tests still remain investigational. Updated background, cross-references, rationale, coding table, and references.
	12/11/2025 Administrative Update. Added new code 0609U. Eff date 01/01/2026
	03/03/2026 Retirement Review. Services to be managed by Evicore.

Health care benefit programs issued or administered by Capital Blue Cross and/or its subsidiaries, Capital Advantage Insurance Company®, Capital Advantage Assurance Company®, and Keystone Health Plan® Central. Independent licensees of the Blue Cross BlueShield Association. Communications issued by Capital Blue Cross in its capacity as administrator of programs and provider relations for all companies.